Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation

Banny S. Wong, Noriaki Manabe, Michael Camilleri

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highlyselective 5-HT4 agonist Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride's high selectivity for the 5-HT4 receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalClinical and Experimental Gastroenterology
Volume3
Issue number1
StatePublished - 2010

Fingerprint

prucalopride
Serotonin Receptors
Receptors, Serotonin, 5-HT4
Constipation
Product Recalls and Withdrawals
Quality of Life
Receptor, Serotonin, 5-HT1B
Cisapride
Gastrointestinal Agents
Phase III Clinical Trials
Therapeutics
Developed Countries
Cardiovascular Diseases
Economics
Safety
serotonin 5 receptor
Pharmaceutical Preparations
Population

Keywords

  • 5-HT agonist
  • Efficacy
  • Prokinetic
  • Prucalopride
  • Serotonin agonist

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation. / Wong, Banny S.; Manabe, Noriaki; Camilleri, Michael.

In: Clinical and Experimental Gastroenterology, Vol. 3, No. 1, 2010, p. 49-56.

Research output: Contribution to journalArticle

@article{e8606bd45b15442297a3c7718b613377,
title = "Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation",
abstract = "Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highlyselective 5-HT4 agonist Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride's high selectivity for the 5-HT4 receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.",
keywords = "5-HT agonist, Efficacy, Prokinetic, Prucalopride, Serotonin agonist",
author = "Wong, {Banny S.} and Noriaki Manabe and Michael Camilleri",
year = "2010",
language = "English (US)",
volume = "3",
pages = "49--56",
journal = "Clinical and Experimental Gastroenterology",
issn = "1178-7023",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation

AU - Wong, Banny S.

AU - Manabe, Noriaki

AU - Camilleri, Michael

PY - 2010

Y1 - 2010

N2 - Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highlyselective 5-HT4 agonist Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride's high selectivity for the 5-HT4 receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.

AB - Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highlyselective 5-HT4 agonist Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride's high selectivity for the 5-HT4 receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.

KW - 5-HT agonist

KW - Efficacy

KW - Prokinetic

KW - Prucalopride

KW - Serotonin agonist

UR - http://www.scopus.com/inward/record.url?scp=77955457389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955457389&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77955457389

VL - 3

SP - 49

EP - 56

JO - Clinical and Experimental Gastroenterology

JF - Clinical and Experimental Gastroenterology

SN - 1178-7023

IS - 1

ER -